Previous 10 | Next 10 |
AcelRx Pharmaceuticals Announces a Second Abstract on DSUVIA® Accepted for Presentation at the ANESTHESIOLOGY® 2022 Annual Meeting PR Newswire Experts from the Uniformed Services University of the Health Sciences conclude that future battlefield medicine ...
AcelRx's 2Q22 Earnings Release and Call provided little tangible news. However, it becomes more and more obvious that ACRX’s management is fully shifting the focus from commercial DSUVIA to launching the Syringes products and Niyad. In light of the ongoing cash burn, the pr...
Shares of micro-cap specialty pharmaceutical company AcelRx Pharmaceuticals ( NASDAQ: ACRX ) have lost 16.8% to $0.26 in Friday premarket trading, despite reporting a Q2 profit versus a loss a year ago and a beat on revenue. It is worth noting that ACRX stock had gaine...
AcelRx Pharmaceuticals, Inc. (ACRX) Q2 2022 Earnings Conference Call August 11, 2022, 04:30 PM ET Company Participants Raffi Asadorian - CFO Vincent Angotti - CEO Pamela Palmer - Chief Medical Officer Conference Call Participants Brandon Folkes - Cant...
AcelRx Pharmaceuticals press release ( NASDAQ: ACRX ): Q2 EPS of $0.48 may not be comparable to consensus of -$0.06. Revenue of $0.57M (+29.5% Y/Y) beats by $0.02M . Projected annual savings of $9 million beginning in June 2022 from realigned cost structure $84...
AcelRx Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update PR Newswire Advanced Niyad™ supply chain development with a focus on obtaining an Emergency Use Authorization in 2023 $0.6 million net revenue in Q2 ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips <img width="1600" height="900" class="aligncenter size-full wp-image-2145006" src="https://investorplace.com/wp-content/uploads/2021/12/achr-stock-1.jpg" alt="The logo for Archer Aviation ( ACHR ) displayed on a smart...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock AcelRx Pharmaceuticals (NASDAQ: ACRX ) stock is seeing major gains on Thursday after announcing a presentation for the upcoming Plastic Surgery: The Meeting 2022 . That meeting is set t...
AcelRx Pharmaceuticals Announces Abstract Acceptance for Podium Presentation at Plastic Surgery: The Meeting 2022 PR Newswire HAYWARD, Calif. , Aug. 11, 2022 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceu...
Major earnings expected after the bell on Thursday include: Illumina ( ILMN ) Rivian Automotive ( RIVN ) Sandstorm Gold Ltd. ( SAND ) Vermilion Energy ( VET ) Wheaton Precious Metals Corp. ( WPM ) For further details see: Notable earnings ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...